Esperion Therapeutics (NASDAQ:ESPR) Target Lowered by Cowen Inc to $30.00

StockMarketDaily.co reports: stock has undergone multiple analysts rating changes in the recent past.  stock Target Lowered by   Cowen Inc on 10/19/2021. In a note to investors, the firm issued a new target price of $30.00. The analysts previously had $60.00 target price.

View More Esperion Therapeutics (NASDAQ:ESPR) Target Lowered by Cowen Inc to $30.00

Esperion Therapeutics (NASDAQ:ESPR) Downgraded by Credit Suisse Group AG to Neutral

Esperion Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Esperion Therapeutics Downgraded by Credit Suisse Group AG on 10/18/2021. In a note to investors, the firm issued a new rating of Neutral. The analysts previously had rating of Outperform.

View More Esperion Therapeutics (NASDAQ:ESPR) Downgraded by Credit Suisse Group AG to Neutral